Outcome analysis in patients with uterine sarcoma |
Yu, Tosol
(Department of Radiation Oncology, Seoul National University College of Medicine)
Kim, Hak Jae (Department of Radiation Oncology, Seoul National University College of Medicine) Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine) Ha, Sung Whan (Department of Radiation Oncology, Seoul National University College of Medicine) Song, Yong-Sang (Cancer Research Institute, Seoul National University College of Medicine) Park, Noh-Hyun (Cancer Research Institute, Seoul National University College of Medicine) Kim, Jae-Won (Cancer Research Institute, Seoul National University College of Medicine) |
1 | Loehrer PJ Sr, Sledge GW Jr, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol 1989;7:1655-9. DOI |
2 | Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway: a histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355-64. DOI |
3 | Vongtama V, Karlen JR, Piver SM, Tsukada Y, Moore RH. Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri. AJR Am J Roentgenol 1976;126:139-47. DOI |
4 | Ayhan A, Aksan G, Gultekin M, et al. Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas. Arch Gynecol Obstet 2009;280:79-85. DOI |
5 | Sorbe B, Johansson B. Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int J Oncol 2008;32:1111-7. |
6 | Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004;93:204-8. DOI |
7 | Olah KS, Gee H, Blunt S, Dunn JA, Kelly K, Chan KK. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer 1991;27:1095-9. DOI |
8 | Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys 2010;76:728-34. DOI |
9 | Ferrer F, Sabater S, Farrus B, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999;44:47-52. DOI |
10 | Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808-18. DOI |
11 | Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786-96. DOI |
12 | Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol 2007;33:91-5. DOI |
13 | Moskovic E, MacSweeney E, Law M, Price A. Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 1993;66:1009-15. DOI |
14 | Tinkler SD, Cowie VJ. Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992. Br J Radiol 1993;66: 998-1001. DOI |
15 | Livi L, Andreopoulou E, Shah N, et al. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol (R Coll Radiol) 2004;16:261-8. DOI |
16 | Sampath S, Gaffney DK. Role of radiotherapy treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 2011;25: 761-72. DOI |
17 | Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177-85. DOI |
18 | Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997;65:493-8. DOI |
19 | Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45. DOI |
20 | Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study): a study of the French Sarcoma Group. Ann Oncol 2013;24:1099-104. DOI |
21 | Gadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;62:25-32. DOI |
22 | Blom R, Guerrieri C, Stal O, Malmstrom H, Simonsen E. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998;68:54-61. DOI |
23 | Wu TI, Chang TC, Hsueh S, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol 2006;100:166-72. DOI |
24 | Sorbe B. Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas. Gynecol Oncol 1985;20:281-9. DOI |
25 | Salazar OM, Dunne ME. The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Biol Phys 1980;6:899-902. DOI |
26 | Park HJ, Kim HJ, Wu HG, et al. The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma. Radiat Oncol J 2011;29:228-35. DOI |
27 | Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 1993;71(4 Suppl):1702-9. DOI |
28 | Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998;68:8-13. DOI |
29 | Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986;12:2127-30. DOI |
30 | Brown L, Petersen I, Haddock M, Lee LJ, Cimbak N, Viswanathan A. Vaginal brachytherapy as the sole radiotherapeutic treatment for stage I carcinosarcoma of the uterus. Brachytherapy 2014;13(Suppl 1):S76-S77. |
31 | Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-50. DOI |
32 | Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas: a randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987;23:1477-83. DOI |
33 | Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75. DOI |
![]() |